IQVIA (NYSE:IQV) Hits New 52-Week Low – What’s Next?

Shares of IQVIA Holdings Inc. (NYSE:IQV) hit a new 52-week low on Wednesday . The company traded as low as $179.12 and last traded at $180.49, with a volume of 637977 shares. The stock had previously closed at $181.39.

Analysts Set New Price Targets

Several equities analysts recently commented on IQV shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Citigroup lowered their price target on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Finally, William Blair reiterated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Trading Down 1.2 %

The company has a market capitalization of $31.25 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a 50 day simple moving average of $193.55 and a 200 day simple moving average of $206.91. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Hedge Funds Weigh In On IQVIA

Institutional investors have recently added to or reduced their stakes in the stock. Synergy Asset Management LLC acquired a new stake in shares of IQVIA in the 4th quarter worth $33,000. GKV Capital Management Co. Inc. acquired a new stake in IQVIA during the fourth quarter worth about $39,000. Lee Danner & Bass Inc. acquired a new position in IQVIA in the 4th quarter valued at about $44,000. Zions Bancorporation N.A. increased its holdings in shares of IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after buying an additional 85 shares during the last quarter. Finally, Versant Capital Management Inc raised its position in shares of IQVIA by 46.0% during the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock valued at $58,000 after buying an additional 93 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.